Yung B Y, Chang F J, Bor A M
Department of Pharmacology, Chang Gung Medical College, Taiwan, R.O.C.
Cancer Lett. 1991 Dec 1;60(3):221-7. doi: 10.1016/0304-3835(91)90117-z.
Actinomycin D treatment (0.001-0.005 micrograms/ml; 0.5-24 h) induced a dose and time response shifting of nucleolar to nuclear fluorescence. In the presence of verapamil, cells were more responsive to actinomycin D. Translocation of protein B23 occurred with lower doses of actinomycin D and in shorter incubation times in the presence of verapamil. Short exposure (0.5 h) of HeLa cells to actinomycin D (0.05-0.25 micrograms/ml) induced 'reversible' translocation of protein B23 as well as 'reversible' inhibition of cell growth and RNA synthesis. Verapamil (5 microM) included in the cell culture after removal of actinomycin D inhibited the recoveries of cell growth, RNA synthesis as well as the corresponding relocalization of protein B23 from the nucleoplasm to nucleoli. These results indicate that verapamil can potentiate the antiproliferating activity of actinomycin D by inhibiting reversibility of its cytotoxicity and suggest clinical application.
放线菌素D处理(0.001 - 0.005微克/毫升;0.5 - 24小时)诱导了核仁荧光向核荧光的剂量和时间依赖性转移。在维拉帕米存在的情况下,细胞对放线菌素D更敏感。在维拉帕米存在时,较低剂量的放线菌素D和较短的孵育时间即可发生蛋白质B23的转位。HeLa细胞短时间(0.5小时)暴露于放线菌素D(0.05 - 0.25微克/毫升)会诱导蛋白质B23的“可逆”转位以及细胞生长和RNA合成的“可逆”抑制。去除放线菌素D后,细胞培养中加入的维拉帕米(5微摩尔)抑制了细胞生长、RNA合成的恢复以及蛋白质B23从核质到核仁的相应重新定位。这些结果表明,维拉帕米可通过抑制放线菌素D细胞毒性的可逆性来增强其抗增殖活性,并提示了其临床应用价值。